Recent advances and applications of molecular docking to g protein-coupled receptors

Molecules

Volumn 22, Issue 2, 2017, Pages

  Bartuzi, Damian ^a   Kaczor, Agnieszka A ^a,b   Targowska Duda, Katarzyna M ^a   Matosiuk, Dariusz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Docking; Drug design; GPCRs

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND; PROTEIN BINDING;

CHEMISTRY; DRUG DESIGN; HUMAN; MOLECULAR DOCKING; PHYSIOLOGY; SIGNAL TRANSDUCTION;

DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 85018182815     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules22020340     Document Type: Review

References (165)

1. Dohlman, H.G. Thematic Minireview Series: New Directions in G Protein-coupled Receptor Pharmacology. J. Biol. Chem. 2015, 290, 19469-19470. [CrossRef].
2. Gloriam, D.E.; Fredriksson, R.; Schiöth, H.B. The G protein-coupled receptor subset of the rat genome. BMC Genom. 2007, 8, 338. [CrossRef] [PubMed].
3. Soppa, J. Two hypotheses-one answer. Sequence comparison does not support an evolutionary link between halobacterial retinal proteins including bacteriorhodopsin and eukaryotic G-protein-coupled receptors. FEBS Lett. 1994, 342, 7-11. [CrossRef].
4. Römpler, H.; Stäubert, C.; Thor, D.; Schulz, A.; Hofreiter, M.; Schöneberg, T. G protein-coupled time travel: Evolutionary aspects of GPCR research. Mol. Interv. 2007, 7, 17-25. [CrossRef] [PubMed].
5. Fredriksson, R.; Lagerström, M.C.; Lundin, L.-G.; Schiöth, H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 2003, 63, 1256-1272. [CrossRef] [PubMed].
6. Gomperts, B.D.; Kramer, I.M.; Tatham, P.E.R. Chapter 4-GTP-binding Proteins and Signal Transduction. In Signal Transduction (Second Edition); Gomperts, B.D., Kramer, I.M., Tatham, P.E.R., Eds.; Academic Press: San Diego, CA, USA, 2009; pp. 81-129.
7. Krauss, G. G Protein-Coupled Signal Transmission Pathways. In Biochemistry of Signal Transduction and Regulation; Wiley-VCH Verlag GmbH & Co. KGaA:Weinheim, Germany, 2003; pp. 179-229.
8. Rankovic, Z.; Brust, T.F.; Bohn, L.M. Biased agonism: An emerging paradigm in GPCR drug discovery. Bioorg. Med. Chem. Lett. 2016, 26, 241-250. [CrossRef] [PubMed].
9. Walther, C.; Ferguson, S.S.G. Minireview: Role of intracellular scaffolding proteins in the regulation of endocrine G protein-coupled receptor signaling. Mol. Endocrinol. 2015, 29, 814-830. [CrossRef] [PubMed].
10. Hubbell, W.L.; Altenbach, C.; Hubbell, C.M.; Khorana, H.G. Rhodopsin structure, dynamics, and activation: A perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv. Protein Chem. 2003, 63, 243-290. [PubMed].
11. Farrens, D.L.; Altenbach, C.; Yang, K.; Hubbell, W.L.; Khorana, H.G. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 1996, 274, 768-770. [CrossRef] [PubMed].
12. Gether, U.; Lin, S.; Ghanouni, P.; Ballesteros, J.A.;Weinstein, H.; Kobilka, B.K. Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J. 1997, 16, 6737-6747. [CrossRef] [PubMed].
13. Yao, X.; Parnot, C.; Deupi, X.; Ratnala, V.R.P.; Swaminath, G.; Farrens, D.; Kobilka, B. Coupling ligand structure to specific conformational switches in the beta2-Adrenoceptor. Nat. Chem. Biol. 2006, 2, 417-422. [CrossRef] [PubMed].
14. Altenbach, C.; Kusnetzow, A.K.; Ernst, O.P.; Hofmann, K.P.; Hubbell, W.L. High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation. Proc. Natl. Acad. Sci. USA 2008, 105, 7439-7444. [CrossRef] [PubMed].
15. Scheerer, P.; Park, J.H.; Hildebrand, P.W.; Kim, Y.J.; Krauss, N.; Choe, H.-W.; Hofmann, K.P.; Ernst, O.P. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008, 455, 497-502. [CrossRef] [PubMed].
16. Rasmussen, S.G.F.; DeVree, B.T.; Zou, Y.; Kruse, A.C.; Chung, K.Y.; Kobilka, T.S.; Thian, F.S.; Chae, P.S.; Pardon, E.; Calinski, D.; et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011, 477, 549-555. [CrossRef] [PubMed].
17. Trzaskowski, B.; Latek, D.; Yuan, S.; Ghoshdastider, U.; Debinski, A.; Filipek, S. Action of molecular switches in GPCRs-Theoretical and experimental studies. Curr. Med. Chem. 2012, 19, 1090-1109. [CrossRef] [PubMed].
18. Yang, X.; Liu, H.; Liu, J.; Li, F.; Li, X.; Shi, L.; Chen, J. Rational Selection of the 3D Structure of Biomacromolecules for Molecular Docking Studies on the Mechanism of Endocrine Disruptor Action. Chem. Res. Toxicol. 2016, 29, 1565-1570. [CrossRef] [PubMed].
19. Kuntz, I.D.; Blaney, J.M.; Oatley, S.J.; Langridge, R.; Ferrin, T.E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288. [CrossRef].
20. Wodak, S.J.; Janin, J. Computer analysis of protein-protein interaction. J. Mol. Biol. 1978, 124, 323-342. [CrossRef].
21. Kaczor, A.A.; Selent, J.; Poso, A. Structure-based molecular modeling approaches to GPCR oligomerization. Methods Cell Biol. 2013, 117, 91-104. [PubMed].
22. Ciancetta, A.; Sabbadin, D.; Federico, S.; Spalluto, G.; Moro, S. Advances in Computational Techniques to Study GPCR-Ligand Recognition. Trends Pharmacol. Sci. 2015, 36, 878-890. [CrossRef] [PubMed].
23. Huang, S.-Y.; Zou, X. Advances and Challenges in Protein-Ligand Docking. Int. J. Mol. Sci. 2010, 11, 3016-3034. [CrossRef] [PubMed].
24. Dror, R.O.; Pan, A.C.; Arlow, D.H.; Borhani, D.W.; Maragakis, P.; Shan, Y.; Xu, H.; Shaw, D.E. Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc. Natl. Acad. Sci. USA 2011, 108, 13118-13123. [CrossRef] [PubMed].
25. Vuong, Q.V.; Nguyen, T.T.; Li, M.S. A New Method for Navigating Optimal Direction for Pulling Ligand from Binding Pocket: Application to Ranking Binding Affinity by Steered Molecular Dynamics. J. Chem. Inf. Model. 2015, 55, 2731-2738. [CrossRef] [PubMed].
26. Kufareva, I.; Katritch, V.; Participants of GPCR Dock 2013; Stevens, R.C.; Abagyan, R. Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: Meeting new challenges. Structure 2014, 22, 1120-1139.
27. Carlson, H.A.; Smith, R.D.; Damm-Ganamet, K.L.; Stuckey, J.A.; Ahmed, A.; Convery, M.A.; Somers, D.O.; Kranz, M.; Elkins, P.A.; Cui, G.; et al. CSAR 2014: A Benchmark Exercise Using Unpublished Data from Pharma. J. Chem. Inf. Model. 2016, 56, 1063-1077. [CrossRef] [PubMed].
28. Gathiaka, S.; Liu, S.; Chiu, M.; Yang, H.; Stuckey, J.A.; Kang, Y.N.; Delproposto, J.; Kubish, G.; Dunbar, J.B.; Carlson, H.A.; et al. D3R grand challenge 2015: Evaluation of protein-ligand pose and affinity predictions. J. Comput. Aided Mol. Des. 2016, 30, 651-668. [CrossRef] [PubMed].
29. Tidgewell, K.; Groer, C.E.; Harding, W.W.; Lozama, A.; Schmidt, M.; Marquam, A.; Hiemstra, J.; Partilla, J.S.; Dersch, C.M.; Rothman, R.B.; et al. Herkinorin analogues with differential beta-Arrestin-2 interactions. J. Med. Chem. 2008, 51, 2421-2431. [CrossRef] [PubMed].
30. Perez-Aguilar, J.M.; Shan, J.; LeVine, M.V.; Khelashvili, G.; Weinstein, H. A functional selectivity mechanism at the serotonin-2A GPCR involves ligand-dependent conformations of intracellular loop 2. J. Am. Chem. Soc. 2014, 136, 16044-16054. [CrossRef] [PubMed].
31. Bartuzi, D.; Kaczor, A.A.; Matosiuk, D. Interplay between Two Allosteric Sites and Their Influence on Agonist Binding in Human μ Opioid Receptor. J. Chem. Inf. Model. 2016, 56, 563-570. [CrossRef] [PubMed].
32. Michino, M.; Beuming, T.; Donthamsetti, P.; Newman, A.H.; Javitch, J.A.; Shi, L. What Can Crystal Structures of Aminergic Receptors Tell Us about Designing Subtype-Selective Ligands? Pharmacol. Rev. 2015, 67, 198-213. [CrossRef] [PubMed].
33. Ballesteros, J.A.; Weinstein, H. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In Methods in Neurosciences; Sealfon, S.C., Ed.; Receptor Molecular Biology; Academic Press: San Diego, CA, USA, 1995; Volume 25, pp. 366-428.
34. Rodríguez, D.; Gao, Z.-G.; Moss, S.M.; Jacobson, K.A.; Carlsson, J. Molecular Docking Screening Using Agonist-Bound GPCR Structures: Probing the A 2A Adenosine Receptor. J. Chem. Inf. Model. 2015, 55, 550-563. [CrossRef] [PubMed].
35. Levitt, D.G.; Banaszak, L.J. POCKET: A Computer Graphics Method for Identifying and Displaying Protein Cavities and Their Surrounding Amino Acids. J. Mol. Graph. 1992, 10, 229-234. [CrossRef].
36. Laskowski, R.A. SURFNET: A program for visualizing molecular surfaces, cavities, and intermolecular interactions. J. Mol. Graph. 1995, 13, 323-330. [CrossRef].
37. Brady, G.P.; Stouten, P.F. Fast prediction and visualization of protein binding pockets with PASS. J. Comput. Aided Mol. Des. 2000, 14, 383-401. [CrossRef] [PubMed].
38. Le Guilloux, V.; Schmidtke, P.; Tuffery, P. Fpocket: An open source platform for ligand pocket detection. BMC Bioinform. 2009, 10, 168. [CrossRef] [PubMed].
39. Brylinski, M.; Feinstein, W.P. e Find Site: Improved prediction of ligand binding sites in protein models using meta-Threading, machine learning and auxiliary ligands. J. Comput. Aided Mol. Des. 2013, 27, 551-567. [CrossRef] [PubMed].
40. Gao, M.; Skolnick, J. A Poc: Large-scale identification of similar protein pockets. Bioinformatics 2013, 29, 597-604. [CrossRef] [PubMed].
41. Kaczor, A.A.; Rutkowska, E.; Bartuzi, D.; Targowska-Duda, K.M.; Matosiuk, D.; Selent, J. Computational methods for studying G protein-coupled receptors (GPCRs). Methods Cell Biol. 2016, 132, 359-399. [PubMed].
42. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662. [CrossRef].
43. Trott, O.; Olson, A.J. Auto Dock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31, 455-461. [CrossRef] [PubMed].
44. Molecular Operating Environment (MOE); Chemical Computing Group Inc.: Montreal, QC, Canada, 2016.
45. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489. [CrossRef] [PubMed].
46. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623. [CrossRef] [PubMed].
47. Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749. [CrossRef] [PubMed].
48. Kitchen, D.B.; Decornez, H.; Furr, J.R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat. Rev. Drug Discov. 2004, 3, 935-949. [CrossRef] [PubMed].
49. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. Auto Dock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785-2791. [CrossRef] [PubMed].
50. Kowalski, P.; Jáskowska, J.; Bojarski, A.J.; Duszý nska, B.; Bucki, A.; Kołaczkowski, M. Evaluation of 1-Arylpiperazine derivative of hydroxybenzamides as 5-HT1A and 5-HT7 serotonin receptor ligands: An experimental and molecular modeling approach. J. Heterocycl. Chem. 2011, 48, 192-198. [CrossRef].
51. Sturlese, M.; Bellanda, M.; Moro, S. NMR-Assisted Molecular Docking Methodologies. Mol. Inform. 2015, 34, 513-525. [CrossRef] [PubMed].
52. Michino, M.; Abola, E.; GPCR Dock 2008 participants; Brooks, C.L.; Dixon, J.S.; Moult, J.; Stevens, R.C. Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat. Rev. Drug Discov. 2009, 8, 455-463. [CrossRef] [PubMed].
53. Kufareva, I.; Rueda, M.; Katritch, V.; Stevens, R.C.; Abagyan, R.; GPCR Dock 2010 participants. Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure 2011, 19, 1108-1126.
54. Totrov, M.; Abagyan, R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins 1997, 29 (Suppl.1), 215-220. [CrossRef].
55. Piotto, S.; Biasi, L.D.; Fino, R.; Parisi, R.; Sessa, L.; Concilio, S. Yada: A novel tool for molecular docking calculations. J. Comput. Aided Mol. Des. 2016, 30, 753-759. [CrossRef] [PubMed].
56. Salmaso, V.; Sturlese, M.; Cuzzolin, A.; Moro, S. DockBench as docking selector tool: The lesson learned from D3R Grand Challenge 2015. J. Comput. Aided Mol. Des. 2016, 30, 773-789. [CrossRef] [PubMed].
57. London, N.; Farelli, J.D.; Brown, S.D.; Liu, C.; Huang, H.; Korczynska, M.; Al-Obaidi, N.F.; Babbitt, P.C.; Almo, S.C.; Allen, K.N.; et al. Covalent Docking Predicts Substrates for Haloalkanoate Dehalogenase Superfamily Phosphatases. Biochemistry (Mosc.) 2015, 54, 528-537. [CrossRef] [PubMed].
58. Yan, F.; Bikbulatov, R.V.; Mocanu, V.; Dicheva, N.; Parker, C.E.; Wetsel, W.C.; Mosier, P.D.; Westkaemper, R.B.; Allen, J.A.; Zjawiony, J.K.; et al. Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor. Biochemistry (Mosc.) 2009, 48, 6898-6908. [CrossRef] [PubMed].
59. Ben-Shimon, A.; Niv, M.Y. Anchor Dock: Blind and Flexible Anchor-Driven Peptide Docking. Structure 2015, 23, 929-940. [CrossRef] [PubMed].
60. Yan, C.; Xu, X.; Zou, X. Fully Blind Docking at the Atomic Level for Protein-Peptide Complex Structure Prediction. Structure 2016, 24, 1842-1853. [CrossRef] [PubMed].
61. Lee, H.; Heo, L.; Lee, M.S.; Seok, C. Galaxy Pep Dock: A protein-peptide docking tool based on interaction similarity and energy optimization. Nucleic Acids Res. 2015, 43, W431-W435. [CrossRef] [PubMed].
62. Jain, A.N. Surflex: Fully Automatic Flexible Molecular Docking Using a Molecular Similarity-Based Search Engine. J. Med. Chem. 2003, 46, 499-511. [CrossRef] [PubMed].
63. Hauser, A.S.; Windshügel, B. LEADS-PEP: A Benchmark Data Set for Assessment of Peptide Docking Performance. J. Chem. Inf. Model. 2016, 56, 188-200. [CrossRef] [PubMed].
64. Manglik, A.; Kruse, A.C.; Kobilka, T.S.; Thian, F.S.; Mathiesen, J.M.; Sunahara, R.K.; Pardo, L.; Weis, W.I.; Kobilka, B.K.; Granier, S. Crystal structure of the β-opioid receptor bound to a morphinan antagonist. Nature 2012, 485, 321-326. [CrossRef] [PubMed].
65. Wong, S.E.; Lightstone, F.C. Accounting for water molecules in drug design. Expert Opin. Drug Discov. 2011, 6, 65-74. [CrossRef] [PubMed].
66. Spyrakis, F.; Cavasotto, C.N. Open challenges in structure-based virtual screening: Receptor modeling, target flexibility consideration and active site water molecules description. Arch. Biochem. Biophys. 2015, 583, 105-119. [CrossRef] [PubMed].
67. De Beer, S.B.A.; Vermeulen, N.P.E.; Oostenbrink, C. The role of water molecules in computational drug design. Curr. Top. Med. Chem. 2010, 10, 55-66. [CrossRef] [PubMed].
68. Huang, N.; Shoichet, B.K. Exploiting ordered waters in molecular docking. J. Med. Chem. 2008, 51, 4862-4865. [CrossRef] [PubMed].
69. Goodford, P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857. [CrossRef] [PubMed].
70. Amadasi, A.; Spyrakis, F.; Cozzini, P.; Abraham, D.J.; Kellogg, G.E.; Mozzarelli, A. Mapping the energetics of water-protein and water-ligand interactions with the "natural" HINT forcefield: Predictive tools for characterizing the roles of water in biomolecules. J. Mol. Biol. 2006, 358, 289-309. [CrossRef] [PubMed].
71. Verdonk, M.L.; Cole, J.C.; Taylor, R. Super Star: A knowledge-based approach for identifying interaction sites in proteins. J. Mol. Biol. 1999, 289, 1093-1108. [CrossRef].
72. Michel, J.; Tirado-Rives, J.; Jorgensen, W.L. Prediction of the water content in protein binding sites. J. Phys. Chem. B 2009, 113, 13337-13346. [CrossRef] [PubMed].
73. Young, T.; Abel, R.; Kim, B.; Berne, B.J.; Friesner, R.A. Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding. Proc. Natl. Acad. Sci. USA 2007, 104, 808-813. [CrossRef] [PubMed].
74. Zheng, M.; Li, Y.; Xiong, B.; Jiang, H.; Shen, J. Water PMF for predicting the properties of water molecules in protein binding site. J. Comput. Chem. 2013, 34, 583-592. [CrossRef] [PubMed].
75. Baroni, M.; Cruciani, G.; Sciabola, S.; Perruccio, F.; Mason, J.S. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): Theory and application. J. Chem. Inf. Model. 2007, 47, 279-294. [CrossRef] [PubMed].
76. Kim, M.; Cho, A.E. Incorporating QM and solvation into docking for applications to GPCR targets. Phys. Chem. Chem. Phys. 2016, 18, 28281-28289. [CrossRef].
77. Lenselink, E.B.; Beuming, T.; Sherman, W.; van Vlijmen, H.W.T.; IJzerman, A.P. Selecting an optimal number of binding site waters to improve virtual screening enrichments against the adenosine A2A receptor. J. Chem. Inf. Model. 2014, 54, 1737-1746. [CrossRef].
78. Yang, Y.; Lightstone, F.C.; Wong, S.E. Approaches to efficiently estimate solvation and explicit water energetics in ligand binding: The use ofWaterMap. Expert Opin. Drug Discov. 2013, 8, 277-287. [CrossRef] [PubMed].
79. Mason, J.S.; Bortolato, A.; Congreve, M.; Marshall, F.H. New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol. Sci. 2012, 33, 249-260. [CrossRef] [PubMed].
80. Yuan, S.; Ghoshdastider, U.; Trzaskowski, B.; Latek, D.; Debinski, A.; Pulawski, W.; Wu, R.; Gerke, V.; Filipek, S. The role of water in activation mechanism of human N-formyl peptide receptor 1 (FPR1) based on molecular dynamics simulations. Plos One 2012, 7, e47114. [CrossRef] [PubMed].
81. Higgs, C.; Beuming, T.; Sherman, W. Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor. ACS Med. Chem. Lett. 2010, 1, 160-164. [CrossRef] [PubMed].
82. Murphy, R.B.; Repasky, M.P.; Greenwood, J.R.; Tubert-Brohman, I.; Jerome, S.; Annabhimoju, R.; Boyles, N.A.; Schmitz, C.D.; Abel, R.; Farid, R.; et al. WScore: A Flexible and Accurate Treatment of Explicit Water Molecules in Ligand-Receptor Docking. J. Med. Chem. 2016, 59, 4364-4384. [CrossRef] [PubMed].
83. Ananthan, S.; Zhang, W.; Hobrath, J.V. Recent advances in structure-based virtual screening of G-protein coupled receptors. AAPS J. 2009, 11, 178-185. [CrossRef] [PubMed].
84. Shoichet, B.K.; Kobilka, B.K. Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol. Sci. 2012, 33, 268-272. [CrossRef] [PubMed].
85. Beuming, T.; Sherman, W. Current assessment of docking into GPCR crystal structures and homology models: Successes, challenges, and guidelines. J. Chem. Inf. Model. 2012, 52, 3263-3277. [CrossRef] [PubMed].
86. Senderowitz, H.; Marantz, Y. G Protein-Coupled Receptors: Target-based in silico screening. Curr. Pharm. Des. 2009, 15, 4049-4068. [CrossRef] [PubMed].
87. Kontoyianni, M.; Liu, Z. Structure-based design in the GPCR target space. Curr. Med. Chem. 2012, 19, 544-556. [CrossRef] [PubMed].
88. Kooistra, A.J.; Leurs, R.; de Esch, I.J.P.; de Graaf, C. From three-dimensional GPCR structure to rational ligand discovery. Adv. Exp. Med. Biol. 2014, 796, 129-157. [PubMed].
89. Sanders, M.P.A.; Roumen, L.; van der Horst, E.; Lane, J.R.; Vischer, H.F.; van Offenbeek, J.; de Vries, H.; Verhoeven, S.; Chow, K.Y.; Verkaar, F.; et al. A prospective cross-screening study on G-protein-coupled receptors: Lessons learned in virtual compound library design. J. Med. Chem. 2012, 55, 5311-5325. [CrossRef] [PubMed].
90. Kołaczkowski, M.; Bucki, A.; Feder, M.; Pawłowski, M. Ligand-optimized homology models of D1 and D2 dopamine receptors: Application for virtual screening. J. Chem. Inf. Model. 2013, 53, 638-648. [CrossRef] [PubMed].
91. Kaczor, A.A.; Silva, A.G.; Loza, M.I.; Kolb, P.; Castro, M.; Poso, A. Structure-Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics. Chem Med Chem 2016, 11, 718-729. [CrossRef] [PubMed].
92. Gandhimathi, A.; Sowdhamini, R. Molecular modelling of human 5-hydroxytryptamine receptor (5-HT2A) and virtual screening studies towards the identification of agonist and antagonist molecules. J. Biomol. Struct. Dyn. 2016, 34, 952-970. [CrossRef] [PubMed].
93. Carlsson, J.; Coleman, R.G.; Setola, V.; Irwin, J.J.; Fan, H.; Schlessinger, A.; Sali, A.; Roth, B.L.; Shoichet, B.K. Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat. Chem. Biol. 2011, 7, 769-778. [CrossRef] [PubMed].
94. Zhang, G.;Wang, K.; Li, X.-D.; Zhang, D.-L.; Xu, F. Discovery of novel antagonists of human neurotensin receptor 1 on the basis of ligand and protein structure. Biomed. Pharmacother. Biomed. Pharmacother. 2016, 84, 147-157. [CrossRef] [PubMed].
95. Daga, P.R.; Polgar, W.E.; Zaveri, N.T. Structure-based virtual screening of the nociceptin receptor: Hybrid docking and shape-based approaches for improved hit identification. J. Chem. Inf. Model. 2014, 54, 2732-2743. [CrossRef] [PubMed].
96. Weiss, D.R.; Bortolato, A.; Tehan, B.; Mason, J.S. GPCR-Bench: A Benchmarking Set and Practitioners' Guide for G Protein-Coupled Receptor Docking. J. Chem. Inf. Model. 2016, 56, 642-651. [CrossRef] [PubMed].
97. Wang, T.; Wu, M.-B.; Chen, Z.-J.; Chen, H.; Lin, J.-P.; Yang, L.-R. Fragment-based drug discovery and molecular docking in drug design. Curr. Pharm. Biotechnol. 2015, 16, 11-25. [CrossRef] [PubMed].
98. Tosh, D.K.; Phan, K.; Gao, Z.-G.; Gakh, A.A.; Xu, F.; Deflorian, F.; Abagyan, R.; Stevens, R.C.; Jacobson, K.A.; Katritch, V. Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. J. Med. Chem. 2012, 55, 4297-4308. [CrossRef] [PubMed].
99. Sirci, F.; Istyastono, E.P.; Vischer, H.F.; Kooistra, A.J.; Nijmeijer, S.; Kuijer, M.;Wijtmans, M.; Mannhold, R.; Leurs, R.; de Esch, I.J.P.; et al. Virtual fragment screening: Discovery of histamine H3 receptor ligands using ligand-based and protein-based molecular fingerprints. J. Chem. Inf. Model. 2012, 52, 3308-3324. [CrossRef] [PubMed].
100. Ranganathan, A.; Stoddart, L.A.; Hill, S.J.; Carlsson, J. Fragment-Based Discovery of Subtype-Selective Adenosine Receptor Ligands from Homology Models. J. Med. Chem. 2015, 58, 9578-9590. [CrossRef] [PubMed].
101. De Graaf, C.; Kooistra, A.J.; Vischer, H.F.; Katritch, V.; Kuijer, M.; Shiroishi, M.; Iwata, S.; Shimamura, T.; Stevens, R.C.; de Esch, I.J.P.; et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. J. Med. Chem. 2011, 54, 8195-8206. [CrossRef] [PubMed].
102. Chen, D.; Ranganathan, A.; IJzerman, A.P.; Siegal, G.; Carlsson, J. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor. J. Chem. Inf. Model. 2013, 53, 2701-2714. [CrossRef] [PubMed].
103. Vass, M.; Schmidt, E.; Horti, F.; Keseru, G.M. Virtual fragment screening on GPCRs: A case study on dopamine D3 and histamine H4 receptors. Eur. J. Med. Chem. 2014, 77, 38-46. [CrossRef] [PubMed].
104. Rodríguez-Espigares, I.; Kaczor, A.A.; Selent, J. In silico Exploration of the Conformational Universe of GPCRs. Mol. Inform. 2016, 35, 227-237. [CrossRef] [PubMed].
105. Tarcsay, A.; Paragi, G.; Vass, M.; Jójárt, B.; Bogár, F.; Keseru, G.M. The impact of molecular dynamics sampling on the performance of virtual screening against GPCRs. J. Chem. Inf. Model. 2013, 53, 2990-2999. [CrossRef] [PubMed].
106. Kohlhoff, K.J.; Shukla, D.; Lawrenz, M.; Bowman, G.R.; Konerding, D.E.; Belov, D.; Altman, R.B.; Pande, V.S. Cloud-based simulations on Google Exacycle reveal ligand modulation of GPCR activation pathways. Nat. Chem. 2013, 6, 15-21. [CrossRef] [PubMed].
107. Bhattacharya, S.; Vaidehi, N. Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor. J. Am. Chem. Soc. 2010, 132, 5205-5214. [CrossRef] [PubMed].
108. Rodríguez, D.; Ranganathan, A.; Carlsson, J. Strategies for improved modeling of GPCR-drug complexes: Blind predictions of serotonin receptors bound to ergotamine. J. Chem. Inf. Model. 2014, 54, 2004-2021. [CrossRef] [PubMed].
109. Weiss, D.R.; Ahn, S.; Sassano, M.F.; Kleist, A.; Zhu, X.; Strachan, R.; Roth, B.L.; Lefkowitz, R.J.; Shoichet, B.K. Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor. ACS Chem. Biol. 2013, 8, 1018-1026. [CrossRef] [PubMed].
110. Schmidt, D.; Bernat, V.; Brox, R.; Tschammer, N.; Kolb, P. Identifying modulators of CXC receptors 3 and 4 with tailored selectivity using multi-Target docking. ACS Chem. Biol. 2015, 10, 715-724. [CrossRef] [PubMed].
111. Rodríguez, D.; Brea, J.; Loza, M.I.; Carlsson, J. Structure-based discovery of selective serotonin 5-HT(1B) receptor ligands. Structure 2014, 22, 1140-1151.
112. Miao, Y.; Goldfeld, D.A.; Moo, E.V.; Sexton, P.M.; Christopoulos, A.; McCammon, J.A.; Valant, C. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor. Proc. Natl. Acad. Sci. USA 2016, 113, E5675-E5684. [CrossRef] [PubMed].
113. Jang, J.W.; Cho, N.-C.; Min, S.-J.; Cho, Y.S.; Park, K.D.; Seo, S.H.; No, K.T.; Pae, A.N. Novel Scaffold Identification of mGlu1 Receptor Negative Allosteric Modulators Using a Hierarchical Virtual Screening Approach. Chem. Biol. Drug Des. 2016, 87, 239-256. [CrossRef] [PubMed].
114. Huang, X.-P.; Karpiak, J.; Kroeze, W.K.; Zhu, H.; Chen, X.; Moy, S.S.; Saddoris, K.A.; Nikolova, V.D.; Farrell, M.S.; Wang, S.; et al. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature 2015, 527, 477-483. [CrossRef] [PubMed].
115. Carrieri, A.; Pérez-Nueno, V.I.; Lentini, G.; Ritchie, D.W. Recent trends and future prospects in computational GPCR drug discovery: From virtual screening to polypharmacology. Curr. Top. Med. Chem. 2013, 13, 1069-1097. [CrossRef] [PubMed].
116. Vass, M.; Kooistra, A.J.; Ritschel, T.; Leurs, R.; de Esch, I.J.; de Graaf, C. Molecular interaction fingerprint approaches for GPCR drug discovery. Curr. Opin. Pharmacol. 2016, 30, 59-68. [CrossRef] [PubMed].
117. Hertig, S.; Latorraca, N.R.; Dror, R.O. Revealing Atomic-Level Mechanisms of Protein Allostery with Molecular Dynamics Simulations. PLoS Comput. Biol. 2016, 12, e1004746. [CrossRef] [PubMed].
118. Wassman, C.D.; Baronio, R.; Demir, O.; Wallentine, B.D.; Chen, C.-K.; Hall, L.V.; Salehi, F.; Lin, D.-W.; Chung, B.P.; Hatfield, G.W.; et al. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat. Commun. 2013, 4, 1407. [CrossRef] [PubMed].
119. Bakan, A.; Nevins, N.; Lakdawala, A.S.; Bahar, I. Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules. J. Chem. Theory Comput. 2012, 8, 2435-2447. [CrossRef] [PubMed].
120. Ivetac, A.; McCammon, J.A. Mapping the druggable allosteric space of G-protein coupled receptors: A fragment-based molecular dynamics approach. Chem. Biol. Drug Des. 2010, 76, 201-217. [CrossRef] [PubMed].
121. Tan, Y.S.; Sledz, P.; Lang, S.; Stubbs, C.J.; Spring, D.R.; Abell, C.; Best, R.B. Using ligand-mapping simulations to design a ligand selectively targeting a cryptic surface pocket of polo-like kinase 1. Angew. Chem. 2012, 51, 10078-10081. [CrossRef] [PubMed].
122. Buch, I.; Giorgino, T.; De Fabritiis, G. Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc. Natl. Acad. Sci. USA 2011, 108, 10184-10189. [CrossRef] [PubMed].
123. Shan, Y.; Kim, E.T.; Eastwood, M.P.; Dror, R.O.; Seeliger, M.A.; Shaw, D.E. How does a drug molecule find its target binding site? J. Am. Chem. Soc. 2011, 133, 9181-9183. [CrossRef] [PubMed].
124. Dror, R.O.; Green, H.F.; Valant, C.; Borhani, D.W.; Valcourt, J.R.; Pan, A.C.; Arlow, D.H.; Canals, M.; Lane, J.R.; Rahmani, R.; et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature 2013, 503, 295-299. [CrossRef] [PubMed].
125. Kruse, A.C.; Ring, A.M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hübner, H.; Pardon, E.; Valant, C.; Sexton, P.M.; et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 2013, 504, 101-106. [CrossRef] [PubMed].
126. Johnston, J.M.; Filizola, M. Showcasing modern molecular dynamics simulations of membrane proteins through G protein-coupled receptors. Curr. Opin. Struct. Biol. 2011, 21, 552-558. [CrossRef] [PubMed].
127. Hurst, D.P.; Grossfield, A.; Lynch, D.L.; Feller, S.; Romo, T.D.; Gawrisch, K.; Pitman, M.C.; Reggio, P.H. A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J. Biol. Chem. 2010, 285, 17954-17964. [CrossRef] [PubMed].
128. Kruse, A.C.; Hu, J.; Pan, A.C.; Arlow, D.H.; Rosenbaum, D.M.; Rosemond, E.; Green, H.F.; Liu, T.; Chae, P.S.; Dror, R.O.; et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 2012, 482, 552-556. [CrossRef] [PubMed].
129. Shaw, D.E.; Deneroff, M.M.; Dror, R.O.; Kuskin, J.S.; Larson, R.H.; Salmon, J.K.; Young, C.; Batson, B.; Bowers, K.J.; Chao, J.C.; et al. Anton, A Special-Purpose Machine for Molecular Dynamics Simulation. Commun. ACM 2008, 51. [CrossRef].
130. Provasi, D.; Bortolato, A.; Filizola, M. Exploring molecular mechanisms of ligand recognition by opioid receptors with metadynamics. Biochemistry (Mosc.) 2009, 48, 10020-10029. [CrossRef] [PubMed].
131. Sabbadin, D.; Moro, S. Supervised molecular dynamics (SuMD) as a helpful tool to depict GPCR-ligand recognition pathway in a nanosecond time scale. J. Chem. Inf. Model. 2014, 54, 372-376. [CrossRef] [PubMed].
132. Hamelberg, D.; Mongan, J.; McCammon, J.A. Accelerated molecular dynamics: A promising and efficient simulation method for biomolecules. J. Chem. Phys. 2004, 120, 11919-11929. [CrossRef] [PubMed].
133. Schneider, S.; Provasi, D.; Filizola, M. How Oliceridine (TRV-130) Binds and Stabilizes a μ-Opioid Receptor Conformational State that Selectively Triggers G Protein-Signaling Pathways. Biochemistry (Mosc.) 2016. [CrossRef] [PubMed].
134. Kappel, K.; Miao, Y.; McCammon, J.A. Accelerated molecular dynamics simulations of ligand binding to a muscarinic G-protein-coupled receptor. Q. Rev. Biophys. 2015, 48, 479-487. [CrossRef] [PubMed].
135. Prasanna, X.; Sengupta, D.; Chattopadhyay, A. Cholesterol-dependent Conformational Plasticity in GPCR Dimers. Sci. Rep. 2016, 6, 31858. [CrossRef] [PubMed].
136. Pluhackova, K.; Gahbauer, S.; Kranz, F.; Wassenaar, T.A.; Böckmann, R.A. Dynamic Cholesterol-Conditioned Dimerization of the G Protein Coupled Chemokine Receptor Type 4. PLoS Comput. Biol. 2016, 12, e1005169. [CrossRef] [PubMed].
137. Bartuzi, D.; Kaczor, A.A.; Matosiuk, D. Activation and allosteric modulation of human μ opioid receptor in molecular dynamics. J. Chem. Inf. Model. 2015, 55, 2421-2434. [CrossRef] [PubMed].
138. Shang, Y.; Yeatman, H.R.; Provasi, D.; Alt, A.; Christopoulos, A.; Canals, M.; Filizola, M. Proposed Mode of Binding and Action of Positive Allosteric Modulators at Opioid Receptors. ACS Chem. Biol. 2016. [CrossRef] [PubMed].
139. Kastner, K.W.; Izaguirre, J.A. Accelerated molecular dynamics simulations of the octopamine receptor using GPUs: Discovery of an alternate agonist-binding position. Proteins 2016, 84, 1480-1489. [CrossRef] [PubMed].
140. Milanos, L.; Saleh, N.; Kling, R.C.; Kaindl, J.; Tschammer, N.; Clark, T. Identification of Two Distinct Sites for Antagonist and Biased Agonist Binding to the Human Chemokine Receptor CXCR3. Angew. Chem. 2016, 55, 15277-15281. [CrossRef] [PubMed].
141. Okimoto, N.; Suenaga, A.; Taiji, M. Evaluation of protein-ligand affinity prediction using steered molecular dynamics simulations. J. Biomol. Struct. Dyn. 2016, 1-11. [CrossRef] [PubMed].
142. Patel, J.S.; Berteotti, A.; Ronsisvalle, S.; Rocchia, W.; Cavalli, A. Steered Molecular Dynamics Simulations for Studying Protein-Ligand Interaction in Cyclin-Dependent Kinase 5. J. Chem. Inf. Model. 2014, 54, 470-480. [CrossRef] [PubMed].
143. Lenselink, E.B.; Louvel, J.; Forti, A.F.; van Veldhoven, J.P.D.; de Vries, H.; Mulder-Krieger, T.; McRobb, F.M.; Negri, A.; Goose, J.; Abel, R.; et al. Predicting Binding Affinities for GPCR Ligands Using Free-Energy Perturbation. ACS Omega 2016, 1, 293-304. [CrossRef].
144. Ferré, S.; Casadó, V.; Devi, L.A.; Filizola, M.; Jockers, R.; Lohse, M.J.; Milligan, G.; Pin, J.-P.; Guitart, X. G protein-coupled receptor oligomerization revisited: Functional and pharmacological perspectives. Pharmacol. Rev. 2014, 66, 413-434. [CrossRef] [PubMed].
145. Salahpour, A.; Angers, S.; Bouvier, M. Functional significance of oligomerization of G-protein-coupled receptors. Trends Endocrinol. Metab. 2000, 11, 163-168. [CrossRef].
146. Milligan, G. G protein-coupled receptor hetero-dimerization: Contribution to pharmacology and function. Br. J. Pharmacol. 2009, 158, 5-14. [CrossRef] [PubMed].
147. Selent, J.; Kaczor, A.A. Oligomerization of G protein-coupled receptors: Computational methods. Curr. Med. Chem. 2011, 18, 4588-4605. [CrossRef] [PubMed].
148. Kaczor, A.A.; Selent, J. Oligomerization of G protein-coupled receptors: Biochemical and biophysical methods. Curr. Med. Chem. 2011, 18, 4606-4634. [CrossRef] [PubMed].
149. Kaczor, A.A.; Makarska-Bialokoz, M.; Selent, J.; de la Fuente, R.A.; Martí-Solano, M.; Castro, M. Application of BRET for studying G protein-coupled receptors. Mini Rev. Med. Chem. 2014, 14, 411-425. [CrossRef] [PubMed].
150. Guixà-González, R.; Ramírez-Anguita, J.M.; Kaczor, A.A.; Selent, J. Simulating G protein-coupled receptors in native-like membranes: From monomers to oligomers. Methods Cell Biol. 2013, 117, 63-90. [PubMed].
151. Lukasiewicz, S.; Polit, A.; Kedracka-Krok, S.; Wedzony, K.; Máckowiak, M.; Dziedzicka-Wasylewska, M. Hetero-dimerization of serotonin 5-HT(2A) and dopamine D(2) receptors. Biochim. Biophys. Acta 2010, 1803, 1347-1358. [CrossRef] [PubMed].
152. Hu, J.; Thor, D.; Zhou, Y.; Liu, T.;Wang, Y.; McMillin, S.M.; Mistry, R.; Challiss, R.A.J.; Costanzi, S.;Wess, J. Structural aspects of M3 muscarinic acetylcholine receptor dimer formation and activation. FASEB J. 2012, 26, 604-616. [CrossRef] [PubMed].
153. Kaczor, A.A.; Selent, J.; Sanz, F.; Pastor, M. Modeling Complexes of Transmembrane Proteins: Systematic Analysis of Protein-Protein Docking Tools. Mol. Inform. 2013, 32, 717-733. [CrossRef] [PubMed].
154. Duarte, J.M.; Biyani, N.; Baskaran, K.; Capitani, G. An analysis of oligomerization interfaces in transmembrane proteins. BMC Struct. Biol. 2013, 13, 21. [CrossRef] [PubMed].
155. Soulier, J.-L.; Russo, O.; Giner, M.; Rivail, L.; Berthouze, M.; Ongeri, S.; Maigret, B.; Fischmeister, R.; Lezoualc'h, F.; Sicsic, S.; et al. Design and synthesis of specific probes for human 5-HT4 receptor dimerization studies. J. Med. Chem. 2005, 48, 6220-6228. [CrossRef] [PubMed].
156. Fanelli, F.; Mauri, M.; Capra, V.; Raimondi, F.; Guzzi, F.; Ambrosio, M.; Rovati, G.E.; Parenti, M. Light on the structure of thromboxane A2 receptor heterodimers. Cell. Mol. Life Sci. 2011, 68, 3109-3120. [CrossRef] [PubMed].
157. Kim, S.-K.; Jacobson, K.A. Computational prediction of homodimerization of the A3 adenosine receptor. J. Mol. Graph. Model. 2006, 25, 549-561. [CrossRef] [PubMed].
158. Canals, M.; Marcellino, D.; Fanelli, F.; Ciruela, F.; de Benedetti, P.; Goldberg, S.R.; Neve, K.; Fuxe, K.; Agnati, L.F.; Woods, A.S.; et al. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 2003, 278, 46741-46749. [CrossRef] [PubMed].
159. Liu, X.; Kai, M.; Jin, L.; Wang, R. Computational study of the heterodimerization between mu and delta receptors. J. Comput. Aided Mol. Des. 2009, 23, 321-332. [CrossRef] [PubMed].
160. Bruno, A.; Guadix, A.E.; Costantino, G. Molecular dynamics simulation of the heterodimeric mGluR2/5HT(2A) complex. An atomistic resolution study of a potential new target in psychiatric conditions. J. Chem. Inf. Model. 2009, 49, 1602-1616. [CrossRef] [PubMed].
161. Kaczor, A.A.; Guixà-González, R.; Carrió, P.; Poso, A.; Dove, S.; Pastor, M.; Selent, J. Multi-Component Protein-Protein Docking Based Protocol with External Scoring for Modeling Dimers of G Protein-Coupled Receptors. Mol. Inform. 2015, 34, 246-255. [CrossRef] [PubMed].
162. Kaczor, A.A.; Guixà-González, R.; Carrió, P.; Obiol-Pardo, C.; Pastor, M.; Selent, J. Fractal dimension as a measure of surface roughness of G protein-coupled receptors: Implications for structure and function. J. Mol. Model. 2012, 18, 4465-4475. [CrossRef] [PubMed].
163. Kaczor, A.A.; Jörg, M.; Capuano, B. The dopamine D2 receptor dimer and its interaction with homobivalent antagonists: Homology modeling, docking and molecular dynamics. J. Mol. Model. 2016, 22, 203. [CrossRef] [PubMed].
164. Jorg, M.; Kaczor, A.A.; Mak, F.S.; Lee, K.C.K.; Poso, A.; Miller, N.D.; Scammells, P.J.; Capuano, B. Investigation of novel ropinirole analogues: Synthesis, pharmacological evaluation and computational analysis of dopamine D2 receptor functionalized congeners and homobivalent ligands. Med Chem Comm 2014, 5, 891-898. [CrossRef].
165. Altuntas, S.; Bozkus, Z.; Fraguela, B.B. GPU Accelerated Molecular Docking Simulation with Genetic Algorithms. In Applications of Evolutionary Computation; Squillero, G., Burelli, P., Eds.; Lecture Notes in Computer Science; Springer International Publishing: Cham, Switzerland, 2016; pp. 134-146.